生物谷报道： 韩国延世大学医学院一个研究小组的科学家２５日宣布，他们发现可以使用药物“特罗凯”治疗无法用药物“易瑞沙”治疗的某类肺癌患者。
据韩国媒体报道，由延世大学医学院肿瘤学科教授金周恒和赵柄哲领导的研究小组２５日表示，对无法用“易瑞沙”（吉非替尼）治疗的２１名非小细胞肺癌患者使用“特罗凯”（盐酸厄替尼）治疗后发现，有６名患者的存活期得到明显延长。
据研究小组科学家介绍，“易瑞沙”和“特罗凯”均属于表皮生长因子受体抑制剂，它们主要用来治疗肺癌。因为两者的作用机制相同，此前韩国医学界认为，用“易瑞沙”治疗无效的肺癌患者同样不适合使用“特罗凯”治疗，因此很少用“特罗凯”替代“易瑞沙”进行治疗。
这个研究小组称，新研究成果已被刊登在最新一期美国《临床肿瘤学杂志》上。（引自新华网）
原始出处:
Journal of Clinical Oncology, Vol 25, No 18 (June 20), 2007: pp. 2528-2533
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.10.4166
Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib
Byoung Chul Cho, Chong-Kun Im, Moo-Suk Park, Se Kyu Kim, Joon Chang, Jong Pil Park, Hye Jin Choi, Yu Jin Kim, Sang-Joon Shin, Joo Hyuk Sohn, Hoguen Kim, Joo Hang Kim
From the Yonsei Cancer Center; Department of Internal Medicine; Lung Cancer Clinic Severance Hospital; and the Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
Address reprint requests to Joo Hang Kim, MD, PhD, Yonsei University College of Medicine, Seodaemun-gu shinchon-dong 134, Seoul, Korea; e-mail: kjhang@yumc.yonsei.ac.kr
Purpose: This study was designed to evaluate the efficacy and toxicity of erlotinib in patients with advanced non–small-cell lung cancer (NSCLC) who experienced disease progression after treatment with gefitinib.
Patients and Methods: The study included stage IIIB/IV recurrent or metastatic NSCLC patients who received two or three prior chemotherapy regimens and showed progressive disease within 4 months of gefitinib therapy discontinuation. Patients received erlotinib 150 mg/d until disease progression or unacceptable toxicity. Epidermal growth factor receptor (EGFR) mutations and other genetic abnormalities were analyzed from available tumor samples.
Results: Patient and disease characteristics (N = 21) included median age 56 years; number of prior chemotherapy regimens (three; n = 11); female sex (n = 11); adenocarcinoma (n = 15); and never-smoker status (n = 11). Among the 17 patients with tumor samples available, EGFR mutations were detected in five. The disease control rate (DCR) and response rate (RR) for all patients were 28.6% and 9.5%, respectively. The median duration of disease control was 125 days. The median time to progression and overall survival were 60 days and 158 days, respectively. Patients who had stable disease (SD) while receiving gefitinib showed significantly higher DCR (75% v 17.6% in non-SD patients; P = .050) and RR (50.0% v 0% in non-SD patients; P = .029). Among 17 patients with biomarker results available, those lacking EGFR mutations who had SD while receiving gefitinib showed significantly higher DCR and RR.
Conclusion: Erlotinib seems to be a potential therapeutic option for the treatment of advanced NSCLC patients with wild-type EGFR who had SD while receiving gefitinib.
B.C.C. and C.-K.I. contributed equally to this work.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
